Effects of Turmeric on Homocysteine and Fetuin-A in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Double-Blind Placebo-Controlled Study

被引:11
|
作者
Ghaffari, Aida [1 ]
Rafraf, Maryam [2 ]
Navekar, Roya [3 ]
Sepehri, Bita [4 ]
Asghari-Jafarabadi, Mohammad [5 ,6 ]
Ghavami, Seyyed-Mostafa [7 ]
Manafi, Nahid [8 ]
机构
[1] Tabriz Univ Med Sci, Fac Nutr & Food Sci, Students Res Comm, Tabriz, Iran
[2] Tabriz Univ Med Sci, Fac Nutr & Food Sci, Dept Community Nutr, Tabriz, Iran
[3] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran
[4] Tabriz Univ Med Sci, Fac Med, Dept Gastroenterol & Hepatol, Tabriz, Iran
[5] Tabriz Univ Med Sci, Rd Traff Injury Res Ctr, Tabriz, Iran
[6] Tabriz Univ Med Sci, Fac Hlth, Dept Stat & Epidemiol, Tabriz, Iran
[7] Tabriz Univ Med Sci, Fac Paramed, Dept Radiol, Tabriz, Iran
[8] Sanjesh Lab, Tehran, Iran
关键词
Turmeric; Homocysteine; Fetuin-A; Nonalcoholic Fatty Liver; INSULIN-RESISTANCE; SERUM FETUIN; ENDOTHELIAL DYSFUNCTION; METABOLIC SYNDROME; CURCUMIN; PLASMA; RATS; ASSOCIATION; OBESITY; RISK;
D O I
10.5812/ircmj.43193
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Elevated levels of homocysteine (Hcy) and fetuin-A are important risk factors for cardiovascular diseases in patients with a nonalcoholic fatty liver disease (NAFLD). There is limited evidence regarding the effects of turmeric on NAFLD. Objectives: This study aimed at investigating the effects of turmeric supplementation on serum levels of Hcy and fetuin-A in patients with NAFLD. Methods: In this double-blind, randomized, controlled clinical trial, 46 NAFLD patients (21 males and 25 females; age range, 20-60 years) with body mass index ranged 24.9 - 40 kg/m(2) were recruited from Sheikh-ol-Raees clinic in Tabriz City, Iran during Nov 2014May 2015. The participants were allocated into the two groups using the block randomization method. The intervention and control groups received 3g of turmeric (n = 23) and placebo (n = 23), daily for 12 weeks. Fasting blood samples were collected at baseline and at the end of the trial for biochemical analysis. Results: Turmeric supplementation significantly decreased serum levels of Hcy, compared with the placebo group at the end of the study (by 27.83%, P = 0.034). No significant difference was observed between the two groups in serum levels of fetuin-A after the intervention (P > 0.05). Serum levels of glucose, insulin and homeostasis model assessment for insulin resistance were declined significantly in the turmeric group (by 1.22%, 17.69% and 19.48%, P = 0.039, P = 0.013 and P = 0.001, respectively) compared to the placebo. Conclusions: Turmeric consumption had beneficial effects on serum Hcy levels andmaybe useful inmanagementof this risk factor in NAFLD patients.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Effects of Turmeric and Curcumin Dietary Supplementation on Human Gut Microbiota: A Double-Blind, Randomized, Placebo-Controlled Pilot Study
    Peterson, Christine T.
    Vaughn, Alexandra R.
    Sharma, Vandana
    Chopra, Deepak
    Mills, Paul J.
    Peterson, Scott N.
    Sivamani, Raja K.
    JOURNAL OF EVIDENCE-BASED INTEGRATIVE MEDICINE, 2018, 23
  • [32] A randomized, double-blind, placebo-controlled study of tetrabenazine in patients with Huntington's disease.
    Marshall, FJ
    MOVEMENT DISORDERS, 2004, 19 (09) : 1122 - 1122
  • [33] A Randomized, Double-blind, Placebo-Controlled Study of Latrepirdine in Patients With Mild to Moderate Huntington Disease
    Kieburtz, Karl
    Landwehrmeyer, Georg B.
    Cudkowicz, Merit
    Dorsey, E. Ray
    Feigin, Andrew
    Hunt, Victoria
    Kayson, Elise
    McDermott, Michael
    Noonberg, Sarah
    Seitz, Wendy
    Soliveri, Paola
    Walker, Francis
    Burgunder, Jean-Marc
    Romero, Irene
    Magara, Anouk
    Stebler, Yanik
    Rickards, Hugh
    Wright, Jan
    De Souza, Jenny
    Barker, Roger A.
    Mason, Sarah
    Di Pietro, Anna
    Goodman, Anna
    O'Keeffe, Deidre
    Langlois, Melanie
    Ferland, Germain
    Verret, Louis
    Chouinard, Sylvain
    Paris, Suzanne
    LePage, Christiane
    Nemeth, Andrea H.
    Merritt, Claire
    Cox, Caroline
    Astbury, Therese
    Murphy, Sarah
    Ahmed, Anwar
    St Marie, Patricia
    Berila, Rose Anne
    Kubu, Cynthia
    Segro, Vicki
    Kumar, Rajeev
    Erickson, Diane
    Schneiders, Jay
    Frucht, Steven
    Wasserman, Paula
    Moskowitz, Carol
    Scott, Burton
    Perry-Trice, Peggy
    Wyne, Sarah
    Soliveri, Paola
    JAMA NEUROLOGY, 2013, 70 (01) : 25 - 33
  • [34] Effects of Amantadine on Tardive Dyskinesia: A Randomized, Double-Blind, Placebo-Controlled Study
    Pappa, Sofia
    Tsouli, Sofia
    Apostolou, George
    Mavreas, Venetsanos
    Konitsiotis, Spiridon
    CLINICAL NEUROPHARMACOLOGY, 2010, 33 (06) : 271 - 275
  • [35] Immunomodulatory Effects of ResistAid™: A Randomized, Double-Blind, Placebo-Controlled, Multidose Study
    Udani, Jay K.
    JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 2013, 32 (05) : 331 - 338
  • [36] Antiplatelet effects of citalopram in patients with ischaemic stroke: A randomized, placebo-controlled, double-blind study
    Kristian Lundsgaard Kraglund
    Janne Kaergaard Mortensen
    Søren Paaske Johnsen
    Grethe Andersen
    Erik Lerkevang Grove
    Scientific Reports, 9
  • [37] Effects of levetiracetam on tardive dyskinesia: A randomized, double-blind, placebo-controlled study
    Woods, Scott W.
    Saksa, John R.
    Baker, C. Bruce
    Cohen, Shuki J.
    Tek, Cenk
    JOURNAL OF CLINICAL PSYCHIATRY, 2008, 69 (04) : 546 - 554
  • [38] Effects of Febuxostat in Early Gout A Randomized, Double-Blind, Placebo-Controlled Study
    Dalbeth, Nicola
    Saag, Kenneth G.
    Palmer, William E.
    Choi, Hyon K.
    Hunt, Barbara
    MacDonald, Patricia A.
    Thienel, Ulrich
    Gunawardhana, Lhanoo
    ARTHRITIS & RHEUMATOLOGY, 2017, 69 (12) : 2386 - 2395
  • [39] Effects of probiotic therapy in critically ill patients: a randomized, double-blind, placebo-controlled study
    Alberda, C
    Gramlich, L
    Field, C
    McCargar, L
    Meddings, J
    Madsen, K
    GASTROENTEROLOGY, 2005, 128 (04) : A281 - A282
  • [40] Antiplatelet effects of citalopram in patients with ischaemic stroke: A randomized, placebo-controlled, double-blind study
    Kraglund, Kristian Lundsgaard
    Mortensen, Janne Kaergaard
    Johnsen, Soren Paaske
    Andersen, Grethe
    Grove, Erik Lerkevang
    SCIENTIFIC REPORTS, 2019, 9 (1)